Navigation Links
Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions
Date:6/28/2011

f them don't even know it. In addition, we now know that at least another 57 million Americans have 'pre-diabetes.'" Diabetes is conservatively estimated to be the seventh leading cause of death in the U.S. Minority populations are disproportionately affected, particularly African Americans and Hispanics. For example, African Americans are 1.8 times more likely to develop type 2 diabetes compared to non-Hispanic whites.

According to the Centers for Disease Control and Prevention (CDC), the rate of new cases of type 2 diabetes has nearly doubled in the U.S. in the last decade with these new cases mirroring an increase in obesity rates - a leading cause of type 2 diabetes.

About IntarciaIntarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the efficacy, convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above body temperature and to deliver them in a constant and consistent manner via its proprietary DUROS drug delivery platform. Intarcia is pursuing a clinical stage development program for type 2 diabetes and has other programs for weight regulation to control obesity.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc. DUROS is a registered trademark of ALZA Corporation licensed to Intarcia Therapeutics, Inc. in certain fields.


'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
2. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
3. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
6. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
7. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
8. SVS 2011: Ziehm Imaging Presents Latest Mobile C-armTechnology for Intraoperative use
9. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
10. Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
11. TGen and PBS-Bio presents 2 abstracts at AACR conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Massachusetts (PRWEB) October 22, 2014 ... announced the release of a new infographic, Understanding ... to create a beautifully designed, easy to follow informative ... transmission, areas of outbreak, symptoms and prevention. , "As ... discovered that the 2014 Ebola outbreak represents not only ...
(Date:10/22/2014)... October 22, 2014 Grace Century, a ... healthcare projects, announces the addition of Dr. Yousef ... its advisory team. Dr. Siddiqui will provide further healthcare ... A graduate of University College Medical School ... in medicine in 2001. With further certification as a ...
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3
... today,announced strong revenue growth and stable net profits despite ... in the US was offset by a strong,performance from ... Darwazah, said "The US operations, in 2007, reported,operating profit ... loss there so in spite of,this $30m plus loss ...
... BioPharma Corp. (TSX, FSE: "HBP") today announced financial results for the second ... , , , ... U.S. Securities and Exchange Commission which became effective on March 12, 2009 ... , Helix received regulatory approval to ...
... TauTaTis, Inc. announces that its lead compound for inhibition ... Alzheimer,s Disease, has been recognized as the most potent ... LRRK2 reported to date. Mutations of this gene ... most genetic frequent cause of Parkinson,s Disease.TauTaTis, lead compound ...
Cached Biology Technology:Helix BioPharma Announces Q2 2009 Financial Results 2Helix BioPharma Announces Q2 2009 Financial Results 3Helix BioPharma Announces Q2 2009 Financial Results 4Helix BioPharma Announces Q2 2009 Financial Results 5Helix BioPharma Announces Q2 2009 Financial Results 6Helix BioPharma Announces Q2 2009 Financial Results 7Helix BioPharma Announces Q2 2009 Financial Results 8Helix BioPharma Announces Q2 2009 Financial Results 9Helix BioPharma Announces Q2 2009 Financial Results 10Helix BioPharma Announces Q2 2009 Financial Results 11Helix BioPharma Announces Q2 2009 Financial Results 12TauTaTis Discovers Potent Inhibitor of Parkinson's Disease Gene Activity 2
(Date:10/16/2014)... Virginia Institute of Marine Science have received a ... to identify the streams and wetlands most vulnerable ... help local governments and citizens conserve these important ... dataset of tidal-marsh observations first gathered by VIMS ... baseline can today,s researchers accurately map the slow ...
(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... skates (skates made of animal bones) are the oldest ... BC. Why people started skating on ice and where ... in several locations spread across Central and North Europe. ... Journal of the Linnean Society of London, Dr Formenti ...
... not immediately engage in a race against time to save ... the global warming and acidification predicted for later this century. ... from around the world in a major new study published ... the public understands that the lack of sustainability in the ...
... MD The Biophysical Society has announced the winners of ... of the Biophysical Society and the International Biophysics Congress ... of this competitive award are selected based on scientific ... a paper at the conference. Each awardee receives ...
Cached Biology News:Major study concludes that global warming is killing off coral 2Biophysical Society announces winners of 2008 Student Travel Awards 2Biophysical Society announces winners of 2008 Student Travel Awards 3Biophysical Society announces winners of 2008 Student Travel Awards 4Biophysical Society announces winners of 2008 Student Travel Awards 5
Immunogen: MBP-fusion protein of the C-terminal region of the a2 subunit (amino acids K581-D670) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... This antibody recognizes murine IRF7 ... with other related IRF proteins. ... murine IRF7 protein was confirmed ... the 293T cells transfected with ...
... Clone/PAD: PS603. Immunogen: Synthetic ... surrounding the phosphorylated Ser603 residue ... Specificity: Specific for synapsin I ... 3). Reactivity: Rat (positive ...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: